Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Coronary Artery Disease | 10 | 2024 | 362 | 3.940 |
Why?
|
| Atherosclerosis | 11 | 2024 | 255 | 3.700 |
Why?
|
| Cardiovascular Diseases | 21 | 2024 | 705 | 3.690 |
Why?
|
| Exercise | 7 | 2024 | 322 | 2.220 |
Why?
|
| Vascular Calcification | 5 | 2024 | 51 | 1.920 |
Why?
|
| Hypertension | 8 | 2024 | 741 | 1.800 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2024 | 376 | 1.550 |
Why?
|
| Risk Factors | 26 | 2024 | 5466 | 1.330 |
Why?
|
| Calcium | 7 | 2024 | 1172 | 1.320 |
Why?
|
| Coronary Vessels | 3 | 2024 | 190 | 1.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2022 | 1176 | 1.100 |
Why?
|
| Myocardial Infarction | 5 | 2023 | 373 | 1.070 |
Why?
|
| Coronary Disease | 1 | 2024 | 260 | 0.860 |
Why?
|
| Cardiology | 2 | 2021 | 115 | 0.830 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2022 | 18 | 0.800 |
Why?
|
| Antihypertensive Agents | 4 | 2022 | 249 | 0.780 |
Why?
|
| Preventive Medicine | 1 | 2021 | 17 | 0.780 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2021 | 36 | 0.760 |
Why?
|
| Obesity, Abdominal | 2 | 2023 | 8 | 0.760 |
Why?
|
| Body Mass Index | 4 | 2021 | 771 | 0.750 |
Why?
|
| Cardiovascular System | 1 | 2021 | 62 | 0.740 |
Why?
|
| Calcinosis | 1 | 2022 | 230 | 0.720 |
Why?
|
| Counseling | 1 | 2022 | 163 | 0.720 |
Why?
|
| Thrombosis | 1 | 2023 | 302 | 0.710 |
Why?
|
| Proprotein Convertase 9 | 1 | 2020 | 20 | 0.710 |
Why?
|
| Waist Circumference | 1 | 2019 | 22 | 0.700 |
Why?
|
| Electrocardiography | 4 | 2023 | 493 | 0.690 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 169 | 0.680 |
Why?
|
| Cardiorespiratory Fitness | 3 | 2024 | 9 | 0.670 |
Why?
|
| Humans | 42 | 2024 | 89063 | 0.650 |
Why?
|
| Primary Prevention | 1 | 2019 | 81 | 0.620 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 557 | 0.610 |
Why?
|
| Sleep | 2 | 2023 | 452 | 0.600 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 1043 | 0.540 |
Why?
|
| Incidence | 6 | 2024 | 1592 | 0.440 |
Why?
|
| Cholesterol, LDL | 2 | 2024 | 223 | 0.420 |
Why?
|
| Cardiac Rehabilitation | 2 | 2023 | 5 | 0.420 |
Why?
|
| Hypolipidemic Agents | 3 | 2023 | 99 | 0.410 |
Why?
|
| Risk Assessment | 7 | 2024 | 2290 | 0.400 |
Why?
|
| Coronary Angiography | 3 | 2024 | 242 | 0.400 |
Why?
|
| Drug Therapy, Combination | 3 | 2024 | 783 | 0.390 |
Why?
|
| Exercise Test | 2 | 2024 | 165 | 0.380 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 3657 | 0.380 |
Why?
|
| American Heart Association | 2 | 2023 | 94 | 0.370 |
Why?
|
| Middle Aged | 15 | 2024 | 25863 | 0.320 |
Why?
|
| Female | 19 | 2024 | 46011 | 0.300 |
Why?
|
| Prognosis | 5 | 2024 | 3773 | 0.300 |
Why?
|
| Prevalence | 2 | 2022 | 1240 | 0.290 |
Why?
|
| Male | 18 | 2024 | 42251 | 0.280 |
Why?
|
| Nutrition Surveys | 3 | 2023 | 109 | 0.270 |
Why?
|
| United States | 8 | 2024 | 6955 | 0.270 |
Why?
|
| Atrial Fibrillation | 2 | 2020 | 350 | 0.270 |
Why?
|
| Aged | 10 | 2024 | 19077 | 0.260 |
Why?
|
| Blood Pressure | 4 | 2023 | 899 | 0.250 |
Why?
|
| Cardiologists | 1 | 2023 | 5 | 0.230 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2024 | 105 | 0.230 |
Why?
|
| Adiposity | 2 | 2023 | 76 | 0.220 |
Why?
|
| Prospective Studies | 3 | 2021 | 4273 | 0.220 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 6777 | 0.210 |
Why?
|
| Heart Failure | 2 | 2023 | 1180 | 0.200 |
Why?
|
| Stroke Volume | 1 | 2024 | 462 | 0.200 |
Why?
|
| Calcium, Dietary | 1 | 2021 | 64 | 0.200 |
Why?
|
| Cause of Death | 2 | 2019 | 266 | 0.190 |
Why?
|
| Education | 1 | 2021 | 58 | 0.190 |
Why?
|
| Random Allocation | 1 | 2021 | 328 | 0.190 |
Why?
|
| Preventive Health Services | 1 | 2021 | 39 | 0.190 |
Why?
|
| Chronic Disease | 1 | 2024 | 948 | 0.190 |
Why?
|
| Time Factors | 2 | 2021 | 5320 | 0.190 |
Why?
|
| Accelerometry | 1 | 2021 | 39 | 0.190 |
Why?
|
| Europe | 1 | 2021 | 321 | 0.180 |
Why?
|
| Endovascular Procedures | 1 | 2024 | 270 | 0.180 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2021 | 59 | 0.180 |
Why?
|
| Needs Assessment | 1 | 2021 | 157 | 0.180 |
Why?
|
| Carotid Arteries | 1 | 2021 | 127 | 0.180 |
Why?
|
| Hypoglycemic Agents | 2 | 2019 | 348 | 0.180 |
Why?
|
| Carotid Stenosis | 1 | 2021 | 115 | 0.170 |
Why?
|
| Telemedicine | 1 | 2023 | 185 | 0.170 |
Why?
|
| Hypercholesterolemia | 1 | 2020 | 159 | 0.160 |
Why?
|
| Morbidity | 1 | 2019 | 149 | 0.160 |
Why?
|
| Obesity | 2 | 2023 | 966 | 0.150 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 273 | 0.150 |
Why?
|
| Biomarkers | 1 | 2024 | 1755 | 0.150 |
Why?
|
| Health Status | 3 | 2024 | 370 | 0.150 |
Why?
|
| High Fidelity Simulation Training | 1 | 2016 | 3 | 0.140 |
Why?
|
| Manikins | 1 | 2016 | 41 | 0.140 |
Why?
|
| Computer-Assisted Instruction | 1 | 2016 | 44 | 0.140 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1149 | 0.130 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 219 | 0.130 |
Why?
|
| Survival Rate | 1 | 2019 | 1889 | 0.130 |
Why?
|
| Proportional Hazards Models | 3 | 2023 | 848 | 0.120 |
Why?
|
| Southeastern United States | 2 | 2023 | 8 | 0.120 |
Why?
|
| Stroke | 1 | 2023 | 982 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 738 | 0.110 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 1670 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2019 | 2863 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 2399 | 0.110 |
Why?
|
| Lipreading | 1 | 1992 | 2 | 0.100 |
Why?
|
| Self Report | 2 | 2024 | 295 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 2335 | 0.100 |
Why?
|
| Aptitude | 1 | 1992 | 10 | 0.100 |
Why?
|
| Software | 1 | 2016 | 665 | 0.100 |
Why?
|
| Adult | 5 | 2023 | 26507 | 0.100 |
Why?
|
| Echocardiography | 1 | 2016 | 937 | 0.100 |
Why?
|
| Lipids | 2 | 2023 | 271 | 0.090 |
Why?
|
| Exercise Tolerance | 1 | 2024 | 53 | 0.060 |
Why?
|
| Actigraphy | 1 | 2023 | 59 | 0.060 |
Why?
|
| Self Efficacy | 1 | 2023 | 54 | 0.060 |
Why?
|
| Dyslipidemias | 1 | 2024 | 106 | 0.050 |
Why?
|
| Walking | 1 | 2023 | 89 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 50 | 0.050 |
Why?
|
| Life Style | 1 | 2023 | 172 | 0.050 |
Why?
|
| Healthy Lifestyle | 1 | 2021 | 8 | 0.050 |
Why?
|
| Circadian Rhythm | 1 | 2023 | 305 | 0.050 |
Why?
|
| Insurance Claim Review | 1 | 2020 | 45 | 0.050 |
Why?
|
| Internal Medicine | 1 | 2023 | 355 | 0.040 |
Why?
|
| Registries | 1 | 2024 | 778 | 0.040 |
Why?
|
| Diabetic Angiopathies | 1 | 2019 | 37 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 1715 | 0.040 |
Why?
|
| Diabetic Nephropathies | 1 | 2019 | 87 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2021 | 711 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2023 | 599 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 423 | 0.040 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2016 | 27 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 771 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1212 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2021 | 9003 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2016 | 448 | 0.030 |
Why?
|
| Language Tests | 1 | 1992 | 37 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2657 | 0.020 |
Why?
|
| Reference Values | 1 | 1992 | 661 | 0.020 |
Why?
|
| Child, Preschool | 1 | 1992 | 3717 | 0.020 |
Why?
|
| Child | 1 | 1992 | 7149 | 0.010 |
Why?
|